Skip to main content
SpringerLink
Log in

Diagnostic, Prognostic and Predictive Biomarkers in Gliomas

  • Chapter
  • First Online:
Principles of Neuro-Oncology

  • 2489 Accesses

Abstract

In recent years, multiple biomarkers have emerged in the field of neuro-oncology, with useful applications in improving diagnostic accuracy, establishing patient’s prognosis and predictive response to available medical therapy. The most frequently associated biomarkers, and their respective alterations, include, IDH1/2 mutation, 1p/19q codeletion, ATRX loss, TP53 mutation, MGMT promoter methylation, BRAF and H3 mutations. In this chapter, we review these biomarkers, but also other less understood ones involved in the diagnosis, prognosis and the treatment of gliomas, such as ABC transporters, AGT mutations, G-CIMP mutation, PTEN mutation, among others. We also include two algorithms for molecular-based decision-making for pediatric and adult gliomas and tables with comprehensive information of biomarkers in gliomas.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012 Apr;6(2):140–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Mukohara T. PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer Targets Ther. 2015 May;7:111–23.

    Article  Google Scholar 

  3. Jansen M, Yip S, Louis DN. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol. 2010 Jul;9(7):717–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Lipp ES, McLendon RE. Tissue is the issue: biomarkers of prognosis and classification in adult gliomas. Semin Oncol Nurs. 2018 Dec;34(5):430–42.

    Article  PubMed  Google Scholar 

  5. Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella D, Webster B, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.

    Article  PubMed  Google Scholar 

  6. Aquilanti E, Miller J, Santagata S, Cahill DP, Brastianos PK. Updates in prognostic markers for gliomas. Neuro Oncol. 2018 Nov 9;20(suppl_7):17–26.

    Article  Google Scholar 

  7. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010 May 18;17(5):510–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Tanboon J, Williams EA, Louis DN. The diagnostic use of immunohistochemical surrogates for signature molecular genetic alterations in gliomas. J Neuropathol Exp Neurol. 2016;75(1):4–18.

    Article  CAS  PubMed  Google Scholar 

  9. Hasselblatt M, Jaber M, Reuss D, Grauer O, Bibo A, Terwey S, et al. Diffuse astrocytoma, IDH-wildtype: a dissolving diagnosis. J Neuropathol Exp Neurol. 2018;77(6):422–5.

    Article  CAS  PubMed  Google Scholar 

  10. Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18(6):e315–29.

    Article  PubMed  Google Scholar 

  11. Griffin CA, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart JD, et al. Identification of der(1;19)(q10;p10) in five Oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol. 2006 Oct;65(10):988–94.

    Article  PubMed  Google Scholar 

  12. Iorgulescu JB, Torre M, Harary M, Smith TR, Aizer AA, Reardon DA, et al. The misclassification of diffuse gliomas: rates and outcomes. Clin Cancer Res. 2019 Jan 11;25(8):2656–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Li Y-X, Shi Z, Aibaidula A, Chen H, Tang Q, Li KK-W, et al. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. Oncotarget. 2016 Oct 4;7(40):64615–30.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Park S-H, Won J, Kim S-I, Lee Y, Park C-K, Kim S-K, et al. Molecular testing of brain tumor. J Pathol Transl Med. 2017 May;51(3):205–23.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Van Den Bent MJ, Brandes AA, Taphoorn MJB, Kros JM, Kouwenhoven MCM, Delattre JY, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344–50.

    Article  PubMed  Google Scholar 

  16. Gibbons RJ, Wada T, Fisher AC, Malik N, Mitson MJ, Steensma DP, et al. Mutations in the chromatin-associated protein ATRX. Hum Mutat. 2008;29(6):796–802.

    Article  CAS  PubMed  Google Scholar 

  17. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Staedtke V, Dzaye OD, Holdhoff M. Actionable molecular biomarkers in primary brain tumors. Trends in Cancer. 2016;2(7):338–49.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Mur P, Mollejo M, Hernández-Iglesias T, De Lope AR, Castresana JS, García JF, et al. Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade. J Neuropathol Exp Neurol. 2015;74(3):241–9.

    Article  CAS  PubMed  Google Scholar 

  20. Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170(6):1062–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Schulz-Heddergott R, Moll UM. Gain-of-function (GOF) mutant p53 as actionable therapeutic target. Cancers (Basel). 2018 Jun 7;10(6):188.

    Article  Google Scholar 

  22. Gillet E, Alentorn A, Doukouré B, Mundwiller E, van Thuij H, Reijneveld JC, et al. TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas. J Neurooncol. 2014 Mar 4;118(1):131–9.

    CAS  PubMed  Google Scholar 

  23. Takami H, Yoshida A, Fukushima S, Arita H, Matsushita Y, Nakamura T, et al. Revisiting TP53 mutations and immunohistochemistry-a comparative study in 157 diffuse gliomas. Brain Pathol. 2015 May 1;25(3):256–65.

    Article  CAS  PubMed  Google Scholar 

  24. Levidou G, El-Habr E, Saetta AA, Bamias C, Katsougiannis K, Patsouris E, et al. P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature. J Neurooncol. 2010;100(3):363–71.

    Article  CAS  PubMed  Google Scholar 

  25. Jin Y, Xiao W, Song T, Feng G, Dai Z. Expression and prognostic significance of p53 in glioma patients: a meta-analysis. Neurochem Res. 2016 Jul 2;41(7):1723–31.

    Article  CAS  PubMed  Google Scholar 

  26. Ständer M, Peraud A, Leroch B, Kreth FW. Prognostic impact ofTP53 mutation status for adult patients with supratentorial World Health Organization grade II astrocytoma or oligoastrocytoma. Cancer. 2004 Sep 1;101(5):1028–35.

    Article  PubMed  Google Scholar 

  27. Wang X, Chen J, Liu J, You C, Liu Y, Mao Q. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide. Ann Surg Oncol. 2014 Apr 19;21(4):1337–44.

    Article  PubMed  Google Scholar 

  28. Mansouri A, Hachem LD, Mansouri S, Nassiri F, Laperriere NJ, Xia D, et al. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol. 2019;21(2):167–78.

    Article  CAS  PubMed  Google Scholar 

  29. Wang HW, Xu ZK, Song Y, Liu YG. Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China. Cancer Gene Ther. 2017;24(5):215–20.

    Article  CAS  PubMed  Google Scholar 

  30. Cantwell-Dorris ER, O’Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011 Mar 1;10(3):385–94.

    Article  CAS  PubMed  Google Scholar 

  31. Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011 Mar 29;6(3):e17948.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Ma C, Feng R, Chen H, Hameed NUF, Aibaidula A, Song Y, et al. BRAF V600E, TERT, and IDH2 mutations in pleomorphic Xanthoastrocytoma: observations from a large case-series study. World Neurosurg. 2018;120:e1225–33.

    Article  PubMed  Google Scholar 

  33. Jones DTW, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of Pilocytic Astrocytomas. Cancer Res. 2008 Nov 1;68(21):8673–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol. 2013 May;37(5):685–98.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Vuong HG, Altibi AMA, Duong UNP, Ngo HTT, Pham TQ, Fung KM, et al. BRAF mutation is associated with an improved survival in glioma—a systematic review and meta-analysis. Mol Neurobiol. 2018;55(5):3718–24.

    CAS  PubMed  Google Scholar 

  36. Lassaletta A, Zapotocky M, Mistry M, Ramaswamy V, Honnorat M, Krishnatry R, et al. Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol. 2017 Sep 1;35(25):2934–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Chan AK-Y, Zhang RR-Q, Aibaidula A, Shi ZF, Chen H, Mao Y, et al. BRAF mutation marks out specific subgroups of glioma. Glioma. 2018;1(5):168.

    Article  Google Scholar 

  38. Horbinski C, Nikiforova MN, Hagenkord JM, Hamilton RL, Pollack IF. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol. 2012 Jun;14(6):777–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Khuong-Quang D-A, Buczkowicz P, Rakopoulos P, Liu X-Y, Fontebasso AM, Bouffet E, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012 Sep 3;124(3):439–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, et al. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol. 2015;129(5):669–78.

    Article  CAS  PubMed  Google Scholar 

  41. Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJJ, et al. Diffuse midline gliomas with histone H3-K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol. 2016;26(5):569–80.

    Article  CAS  PubMed  Google Scholar 

  42. Kleinschmidt-Demaster BK, Mulcahy-Levy JM. H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis. Clin Neuropathol. 2018;37(2):56–63.

    Google Scholar 

  43. Meyronet D, Esteban-Mader M, Bonnet C, Joly M-O, Uro-Coste E, Amiel-Benouaich A, et al. Characteristics of H3 K27M-mutant gliomas in adults. Neuro Oncol. 2017 Aug 1;19(8):1127–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Guadagno E, Vitiello M, Francesca P, Calì G, Caponnetto F, Cesselli D, et al. PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype. Oncotarget. 2017 Aug 29;8(35):59282–300.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Szopa W, Burley TA, Kramer-Marek G, Kaspera W. Diagnostic and therapeutic biomarkers in glioblastoma: current status and future perspectives. Biomed Res Int. 2017 Feb 20;2017:1–13.

    Article  Google Scholar 

Further Reading

  • Barthel FP, Wesseling P, Verhaak RGW. Reconstructing the molecular life history of gliomas. Acta Neuropathol. 2018;135(5):649–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dréan A, Rosenberg S, Lejeune F-X, Goli L, Nadaradjane AA, Guehennec J, et al. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma. J Neuro-Oncol. 2018 Jul 8;138(3):479–86.

    Article  Google Scholar 

  • Malric L, Monferran S, Gilhodes J, Boyrie S, Dahan P, Skuli N, et al. Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update. Oncotarget. 2017 Oct 17;8(49):86947–68.

    Article  PubMed  PubMed Central  Google Scholar 

  • Montano N, Alessandris QGD, Izzo A, Fernandez E, Pallini R. Biomarkers for glioblastoma multiforme: status quo. J Clin Transl Res. 2016;2(1):3–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Perdomo-Pantoja A, Mejía-Pérez SI, Gómez-Flores-Ramos L, Lara-Velazquez M, Orillac C, Gómez-Amador JL, et al. Renin angiotensin system and its role in biomarkers and treatment in gliomas. J Neuro-Oncol. 2018;138(1):1–15.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank Alejandro Lafuente for his help in editing the figures.

Author information

Authors and Affiliations

  1. Facultad de Medicina, PECEM, Universidad Nacional Autónoma de México, Mexico City, Mexico

    José Alberto Carlos-Escalante

  2. Department of Neurosurgery, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico

    Juan Pablo Calderón

  3. Subdirection of basic research, Instituto Nacional de Cancerología, Mexico City, Mexico

    Talia Wegman-Ostrosky

Authors
  1. José Alberto Carlos-Escalante
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juan Pablo Calderón
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Talia Wegman-Ostrosky
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Neurosurgery, Aurora Neuroscience Innovation Institute, Milwaukee, WI, USA

    Alejandro Monroy-Sosa

  2. Department of Neurosurgery, Aurora Neuroscience Innovation Institute, Milwaukee, WI, USA

    Srikant S. Chakravarthi

  3. Instituto Nacional de Cancerología, Mexico City, Mexico

    Jaime G. de la Garza-Salazar

  4. Instituto Nacional de Cancerología, Mexico City, Mexico

    Abelardo Meneses Garcia

  5. Neeka Health, LLC, Milwaukee, WI, USA

    Amin B. Kassam

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Carlos-Escalante, J.A., Calderón, J.P., Wegman-Ostrosky, T. (2021). Diagnostic, Prognostic and Predictive Biomarkers in Gliomas. In: Monroy-Sosa, A., Chakravarthi, S.S., de la Garza-Salazar, J.G., Meneses Garcia, A., Kassam, A.B. (eds) Principles of Neuro-Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-54879-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-54879-7_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-54878-0

  • Online ISBN: 978-3-030-54879-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation